FSD Pharma Inc
CNSX:HUGE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
FSD Pharma Inc
Cash from Financing Activities
FSD Pharma Inc
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
F
|
FSD Pharma Inc
CNSX:HUGE
|
Cash from Financing Activities
-$3.1m
|
CAGR 3-Years
4%
|
CAGR 5-Years
275%
|
CAGR 10-Years
N/A
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Cash from Financing Activities
-$742m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
Canopy Growth Corp
TSX:WEED
|
Cash from Financing Activities
CA$269.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-1%
|
CAGR 10-Years
21%
|
|
|
Cronos Group Inc
TSX:CRON
|
Cash from Financing Activities
-$19.9m
|
CAGR 3-Years
-90%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
N/A
|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Cash from Financing Activities
$25.2m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Cash from Financing Activities
CA$5.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-9%
|
|
FSD Pharma Inc
Glance View
FSD Pharma, Inc. is a specialty biotech pharmaceutical research and development company. The company is headquartered in Toronto, Ontario and currently employs 10 full-time employees. The company went IPO on 2018-05-29. The Company, through its subsidiary, FSD Biosciences Inc., is focused on pharmaceutical research and development (R&D) of its lead compound, FSD 201, ultra-micronized Palmitoyl (PEA). FSD 201 stabilizes mast cells of the human body and down-regulate the proinflammatory cytokines to effectuate an anti-inflammatory response. Lucid Psycheceuticals Inc., a subsidiary of the Company, has worldwide rights to compounds shown to prevent and reverse the biochemical mechanisms of progressive multiple sclerosis in multiple preclinical animal models. Additionally, the Company is focused on develop a psychoactive (psychedelic-based) therapeutic of neurodegenerative disorders.
See Also
What is FSD Pharma Inc's Cash from Financing Activities?
Cash from Financing Activities
38.2m
USD
Based on the financial report for Dec 31, 2021, FSD Pharma Inc's Cash from Financing Activities amounts to 38.2m USD.
What is FSD Pharma Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
275%
Over the last year, the Cash from Financing Activities growth was 58%. The average annual Cash from Financing Activities growth rates for FSD Pharma Inc have been 4% over the past three years , 275% over the past five years .
